Abstract
Since the description of Xp11.2 translocation renal cell carcinoma as a clinicopathologic entity in 2001, it has attracted increasing attention. This study focused on the oncologic efficacy and feasibility of nephron-sparing surgery (NSS)in this rare tumor. The findings showed that NSS is not recommended for adult Xp11.2 translocation renal carcinoma atcT1bstage due to the possibility of increased risk for postoperative recurrence and metastasis. The results warrant large-scale studies and long-term follow-up evaluation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
